Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Jaya Sangodkar(Pediatrics and Genetics), Goutham Narla(Pediatrics and Genetics), Michael Ohlmeyer(Princeton Satellite Systems (United States)), Janna Kiselar(University School), Sudeh Izadmehr(Icahn School of Medicine at Mount Sinai), Rita Tohmé(Case Western Reserve University), Kimberly McClinch(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Qiaonan Duan(Icahn School of Medicine at Mount Sinai), Daniel McQuaid(Icahn School of Medicine at Mount Sinai), Rui Yuan(Case Western Reserve University), Manish Datt(Guru Nanak Eye Centre), Avi Ma’ayan(Icahn School of Medicine at Mount Sinai), Vickram Gidwani(Icahn School of Medicine at Mount Sinai), Yiannis A. Ioannou(Icahn School of Medicine at Mount Sinai), Neelesh Sharma(Bayer (United States)), Shozeb Haider(University College London), Danica Wiredja(Case Western Reserve University), Caitlin M. O’Connor(University of Michigan), Giridharan Gokulrangan(University of Kansas), Edward Y. Chen(Icahn School of Medicine at Mount Sinai), Divya Hoon(Icahn School of Medicine at Mount Sinai), Caroline Farrington(Case Western Reserve University), Agnes Stachnik(Icahn School of Medicine at Mount Sinai), Rita A. Avelar(University of Michigan), David B. Kastrinsky(Icahn School of Medicine at Mount Sinai), Daniel Léonard(Case Western Reserve University), Elena Svenson(Case Western Reserve University), Blake E. Smith(Yale University), Daniela Schlatzer(Case Western Reserve University), H.M. Giannini(Lung Institute), Mark R. Chance(Case Western Reserve University), David L. Brautigan(University of Virginia), Alice C. Levine(Icahn School of Medicine at Mount Sinai), Analisa DiFeo(University of Michigan), Nilesh Zaware(Icahn School of Medicine at Mount Sinai), Rosalie C. Sears(Oregon Health & Science University), Wenqing Xu(Shanghai Changzheng Hospital), Abbey Perl(Northwestern University), Shen Yao(Icahn School of Medicine at Mount Sinai), Zhizhi Wang(University of Washington), Lifu Wang(Kingmed Diagnostics), Alain Borczuk(Cornell University), Sahar Mazhar(University of Michigan), Neil S. Dhawan(Tisch Hospital)
Cited by 200
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
|Genes & Development|2000|1.4k